Sodium-dependent glucose transporter 2 (SGLT2) inhibitors (canagliflozin (27), luseogliflozin (28)) are promising drugs that can reduce ALT levels and alleviate hepatic steatosis and fibrosis (29). This evidence concerns the gene SLC5A2 and fatty liver disease.